Altabax Review Highlights Ethical Use Of Placebo In Pediatric Populations
This article was originally published in Pharmaceutical Approvals Monthly
GlaxoSmithKline’s pivotal trial for Altabax provided strong evidence that it could be ethical to use a placebo and withhold treatment for dermatological indications – even in a pediatric population – as long as safety measures were employed, FDA reviewers concurred.
You may also be interested in...
NovaBay is a step closer to commercializing the first non-antibiotic for treating an infection typically treated with antibiotics, now that its topical gel yielded a 90 percent cure rate in a Phase IIa proof-of-concept trial against impetigo
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.